SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA approval for generic Femhrt Tablets

29 Dec 2015 Evaluate

Lupin has received final approval for its Fyavolv Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) from the United States Food and Drug Administration (USFDA) to market a generic version of Warner Chilcott’s Femhrt Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg). The pharma major’s US subsidiary, Lupin Pharmaceuticals Inc. shall commence promoting the product in the US shortly.

Lupin’s Fyavolv Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg) are the AB rated generic equivalent of Warner Chilcott’s Femhrt Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg). It is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. Femhrt had US sales of $39.9 million, as per IMS MAT September 2015.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. 


Lupin Share Price

2330.00 5.75 (0.25%)
20-Apr-2026 10:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.40
Dr. Reddys Lab 1236.90
Cipla 1236.95
Zydus Lifesciences 942.05
Lupin 2330.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×